We served as lead counsel to a world-renowned children’s research hospital in its efforts to obtain a Certificate of Need (CON) to replace and relocate the majority of its existing inpatient facilities at its campus in Memphis, Tennessee. Each of the 54 replacement inpatient rooms will feature several innovations, including an adjoining parent room and placement of all major equipment on ceiling-mounted booms in order to maximize the available space. The $62 million project was unanimously approved by state regulators.
CON Approved for Leading Children’s Research Hospital
You Also May Be Interested In:
Representation of Mallinckrodt Pharmaceuticals, a global pharmaceutical manufacturer, in numerous cases in courts across Tennessee, Kentucky, and Virginia
Successful Defense of National Home Healthcare Provider in Appealing $18 Million Extrapolated Overpayment Resulting from UPIC Audit
We successfully defended a national home healthcare provider in appealing an $18 million extrapolated overpayment resulting from a UPIC audit.
Lead Counsel to POINT Biopharma Inc. in its Proposed SPAC Business Combination with Research Alliance Corp. I
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.